Single spike mutation differentiating XBB.1 and XBB.1.5 enhances SARS-CoV-2 cell-to-cell transmission and facilitates serum-mediated enhancement

Front Immunol. 2024 Nov 27:15:1501200. doi: 10.3389/fimmu.2024.1501200. eCollection 2024.

Abstract

Introduction: The ongoing emergence of SARS-CoV-2 variants poses significant challenges to existing therapeutics. The spike (S) glycoprotein is central to both viral entry and cell-to-cell transmission via syncytia formation, a process that confers resistance to neutralizing antibodies. The mechanisms underlying this resistance, particularly in relation to spike-mediated fusion, remain poorly understood.

Methods: We analyzed two clinical SARS-CoV-2 isolates differing by a single amino acid substitution in the S protein. Using biochemical and cell-based assays, we evaluated entry kinetics, syncytia formation, and the neutralizing efficacy of convalescent sera. These parameters were further correlated with S-mediated cell-cell fusion activity.

Results: The single amino acid substitution significantly altered entry kinetics and enhanced syncytia formation. This modification did not diminished the neutralizing capacity of convalescent sera, but it increased the efficiency of S-induced cell-cell fusion. These findings highlight the mutation's impact on viral transmissibility and immune evasion.

Discussion: Our study demonstrates that even minor changes in the S protein can profoundly influence SARS-CoV-2 transmissibility and resistance to antibody-mediated neutralization. Understanding the molecular basis of S-mediated cell-cell fusion is crucial for anticipating the impact of emerging variants and developing next-generation therapeutic strategies. These insights provide a framework for predicting variant fitness and optimizing treatment approaches against future SARS-CoV-2 variants.

Keywords: COVID-19; SARS-CoV-2; Spike; XBB.1; XBB.1.5; fusion; neutralizing antibodies.

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Viral* / immunology
  • COVID-19* / immunology
  • COVID-19* / transmission
  • COVID-19* / virology
  • Cell Fusion
  • Chlorocebus aethiops
  • Giant Cells / virology
  • Humans
  • Mutation
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • SARS-CoV-2* / physiology
  • Spike Glycoprotein, Coronavirus* / genetics
  • Spike Glycoprotein, Coronavirus* / immunology
  • Virus Internalization*

Substances

  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Antibodies, Neutralizing
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by EU funding within NextGenerationEU – Mission 4 Component 1 -MUR PNRR INFACT - One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases – project no. PE00000007 - CUP B43C22000690006.